What Inspectors Expect: Documentation Based on Inspection Type

Why Documentation Standards Vary by Inspection Type

Regulatory inspections—whether routine, for-cause, or triggered by a marketing application—are fundamentally documentation-driven. Authorities such as the FDA, EMA, and MHRA scrutinize trial records to evaluate GCP compliance, subject safety, and data integrity. However, the specific documentation focus may vary depending on the type of inspection.

Routine inspections typically involve a comprehensive review of standard documents across all trial phases. In contrast, for-cause inspections focus on known concerns such as data discrepancies, safety issues, or prior audit findings. Understanding what documents are prioritized in each inspection type helps teams prepare and present their records effectively.

Core Documentation Required in All Inspections

Regardless of inspection type, certain essential documents are universally expected. These include:

• Trial Master File (TMF/eTMF): Complete and current, including protocols, amendments, investigator brochures, and IRB/EC approvals.
• Informed Consent Documents: All versions with subject signatures and IRB approvals.
• Delegation of Duties Log (DoDL): With signatures, version control, and dated entries.
• Subject Case Report Forms (CRFs): Aligned with source documentation and EDC entries.
• Monitoring Visit Reports: Including follow-up letters and resolution documentation.
• Adverse Event (AE) and SAE Reports: Along with expedited reporting records.
• Training Records: GCP, protocol-specific, and system training logs.
• Investigational Product (IP) Documentation: Accountability logs, shipping records, and destruction certificates.

Ensure all records are easily retrievable and consistent with the trial database entries and the TMF structure.

Documentation Emphasis in Routine Inspections

Routine inspections follow a holistic review model and assess whether the sponsor and site maintain compliance over time. The documentation typically examined includes:

• Full chronology of protocol amendments and approvals
• Enrollment logs and screening failures with rationale
• Monitoring plan and site communication records
• Vendor qualification and oversight documents
• Annual safety reports and IRB communications
• Site training trackers and ongoing education updates

Inspectors may ask for retrospective TMF QC reports, indicating whether documents were filed timely and indexed correctly. Gaps in routine inspection documentation often result in “Voluntary Action Indicated (VAI)” or “Official Action Indicated (OAI)” findings.

For-Cause Inspections: Documentation Under the Microscope

For-cause inspections are narrower but deeper. The documentation focus is often dictated by the reason for inspection, which may include:

• Subject safety concerns or reported deaths
• Protocol deviations or site misconduct
• Data integrity issues or whistleblower complaints

In such cases, expect intense scrutiny on the following:

• Audit trail logs from EDC, eTMF, and safety systems
• Version history of key source documents
• Timeline of informed consent for affected subjects
• Root cause analysis and CAPA documentation
• Communication records between sponsor, CRO, and site
• SAE narrative reports and DSMB communications

Be prepared to provide supporting evidence such as system validation records and user access logs if electronic systems are implicated.

Marketing Application Inspections: Registration-Linked Documentation

Inspections tied to a New Drug Application (NDA), Biologics License Application (BLA), or Marketing Authorization Application (MAA) focus on pivotal trials. Documentation reviewed includes:

• Patient eligibility records and randomization logs
• Blinding/unblinding records and reconciliation reports
• Complete audit trail exports for critical data
• Drug accountability forms with storage conditions
• Data transfer validation reports (e.g., lab to EDC)
• PK/PD sample chain of custody logs

Inspectors compare the Clinical Study Report (CSR) submitted in the application with the source data and verify whether discrepancies exist. Referencing tools like Japan’s RCT Portal can help sponsors track trials that underwent marketing inspection reviews globally.

Best Practices to Ensure Inspection-Ready Documentation

Regardless of inspection type, organizations should implement the following strategies to maintain readiness:

• Use a TMF Quality Control checklist during and after trial conduct
• Enable real-time document version tracking with audit trail functionality
• Train site and sponsor staff on file locations and system access procedures
• Ensure translations are available for non-English source documents
• Conduct mock inspections and document retrieval drills every 6–12 months

When preparing for an inspection, always conduct a documentation gap analysis. Use this to triage document correction and finalization tasks well before the inspector arrives.

Conclusion: Documentation is Your Best Defense

Whether facing a routine, for-cause, or marketing-related inspection, documentation serves as the primary evidence of compliance and integrity. Knowing which documents are expected in each context—and preparing them accordingly—can make the difference between a successful inspection and a Form 483. Prioritize a clean, consistent, and accessible documentation system to safeguard your trial’s credibility and regulatory approval pathway.